
Bioage Labs Drops Obesity Drug Amid Shareholder Lawsuit: A Charming and Eccentric Take on BioA’s Surprising Decision
BioAge Labs Abandons Obesity Drug Development, Shifts Focus to Neuroinflammation In a surprising turn of events, BioAge Labs, Inc. (BIOA), a San Francisco-based biotech company, has announced that it is abandoning the development of its lead obesity candidate, azelaprag. This decision comes just weeks after the company halted a Phase 2 trial for the drug,…